AIDS Therapies

Additional HE2000 Clinical Data Reported

Published in AIDS Weekly, January 8th, 2001

Hollis-Eden Pharmaceuticals, Inc. (HEPH) announced presentations of HE2000 clinical data at the "Frontiers in Drug Development for Antiretroviral Therapies" (HIV DART) Meeting, held in San Juan, Puerto Rico, December 17-21, 2000.

HE2000 is the lead investigational compound in a new class of immune regulating hormones and hormone analogs being developed by Hollis-Eden. Data presented are from an interim analysis of 37 patients through three treatment courses in the company's Phase I/II South African clinical trial in treatment-naive HIV patients.

Highlights of the results include statistically significant increases throughout the five-month treatment...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2001-01-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry